Guardant Health (NASDAQ:GH) Price Target Raised to $70.00 at Stifel Nicolaus

Guardant Health (NASDAQ:GH) had its price target lifted by Stifel Nicolaus from $60.00 to $70.00 in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts also recently weighed in on the stock. Wolfe Research upgraded shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price target on the stock in a report on Thursday. BTIG Research set a $80.00 target price on Guardant Health in a report on Thursday. Guggenheim boosted their price target on Guardant Health from $56.00 to $67.00 and gave the stock a “buy” rating in a research report on Thursday. Mizuho upped their price target on Guardant Health from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Evercore ISI raised Guardant Health to a “strong-buy” rating in a report on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating and twenty-two have given a Buy rating to the company. Based on data from MarketBeat.com, Guardant Health has a consensus rating of “Buy” and an average target price of $64.75.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $60.18 on Thursday. The firm has a market cap of $7.51 billion, a price-to-earnings ratio of -17.96 and a beta of 1.46. The stock has a 50-day simple moving average of $55.34 and a 200-day simple moving average of $48.72. Guardant Health has a 52-week low of $20.14 and a 52-week high of $68.00.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. The company’s quarterly revenue was up 31.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.84) EPS. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Guardant Health will post -2.9 earnings per share for the current year.

Insider Buying and Selling at Guardant Health

In other news, CEO Helmy Eltoukhy sold 300,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total value of $17,835,000.00. Following the completion of the sale, the chief executive officer directly owned 2,123,499 shares of the company’s stock, valued at approximately $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Amirali Talasaz sold 100,000 shares of the firm’s stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the completion of the sale, the chief executive officer owned 1,971,830 shares in the company, valued at approximately $100,326,710.40. The trade was a 4.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 402,691 shares of company stock valued at $23,069,965 in the last 90 days. 6.10% of the stock is currently owned by insiders.

Institutional Trading of Guardant Health

A number of hedge funds have recently bought and sold shares of GH. Janney Montgomery Scott LLC acquired a new stake in Guardant Health in the 1st quarter worth $232,000. Intech Investment Management LLC grew its position in Guardant Health by 37.3% during the first quarter. Intech Investment Management LLC now owns 60,187 shares of the company’s stock worth $2,564,000 after buying an additional 16,363 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in Guardant Health during the first quarter worth about $866,000. Fifth Third Bancorp bought a new position in Guardant Health during the first quarter valued at about $279,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Guardant Health in the 1st quarter valued at approximately $442,000. 92.60% of the stock is owned by institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.